VNDA Share Price Performance
US$7.89
3.04 (62.68%)
64.1% undervalued intrinsic discount
US$22.00
Fair Value
Price US$7.89
AnalystHighTarget US$22.00
AnalystConsensusTarget US$12.67
AnalystLowTarget US$7.50
Fair ValueUS$22.00
Share Pricen/a
Vanda Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 34 Fair Values set on narratives written by author
VNDA Community Narratives
AN
Fair Value US$22 64.1% undervalued intrinsic discount
Diversified Pipeline And Global Reach Will Advance Neurology Markets
1users have liked this narrative
1users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$12.67 37.7% undervalued intrinsic discount
Expanding Global CNS And Orphan Therapies Will Unlock Future Potential
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value US$7.5 5.2% overvalued intrinsic discount
Rising Costs And Concentration Will Thwart Stability Yet Spark Recovery
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Rising Costs And Concentration Will Thwart Stability Yet Spark Recovery
Key Takeaways Reliance on a narrow commercial base and high R&D costs create uncertainty for revenue growth, net margins, and operating leverage amid competitive and regulatory pressures. Expansion efforts and pipeline diversification face challenges from international pricing, reimbursement delays, and market volatility, potentially limiting returns from new launches and partnerships.Read more
48
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$7.5
5.2% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Profit Margin
10.9%
Future PE
12.05x
Price in 2029
US$9.11
Diversified Pipeline And Global Reach Will Advance Neurology Markets
Key Takeaways Fanapt and Bysanti launches are set to deliver rapid, sustained revenue growth and significant margin improvement due to expanded prescriber engagement and high-margin patient transitions. Diversified late-stage pipeline and scalable commercial platform drive multi-year revenue resilience, with focus on specialty therapies providing durable margins and global market access.Read more
72
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
2users have followed this narrative
AN
US$22
64.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
4.41%
Future PE
82.02x
Price in 2029
US$26.73
Expanding Global CNS And Orphan Therapies Will Unlock Future Potential
Key Takeaways Expansion of new product launches and increased sales efforts are driving strong growth in psychiatric and neurological treatment markets globally. Advancing a diverse pipeline in CNS and rare diseases reduces reliance on older products and supports long-term profitability through market exclusivity and improved margins.Read more
145
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
US$12.67
37.7% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
1.78%
Future PE
122.51x
Price in 2028
US$15.3
Trending Discussion
Recently Updated Narratives
AN
VNDA: Psychiatry Concentration Risk Will Drive A Cautious Forward Outlook
Fair Value: US$7.5 5.2% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
VNDA: Jet Lag Setback Will Keep Focus On 2026 Earnings Outlook
Fair Value: US$22 64.1% undervalued intrinsic discount
2 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Expanding Global CNS And Orphan Therapies Will Unlock Future Potential
Fair Value: US$12.67 37.7% undervalued intrinsic discount
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vanda Pharmaceuticals Inc. Key Details
About VNDA
- Founded
- 2002
- Employees
- 533
- CEO
- WebsiteView website
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company’s products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
